Literature DB >> 12601500

The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Ina Weiner1.   

Abstract

RATIONALE: Latent inhibition (LI), namely, poorer performance on a learning task involving a previously pre-exposed non-reinforced stimulus, is disrupted in the rat by the dopamine (DA) releaser amphetamine which produces and exacerbates psychotic (positive) symptoms, and this is reversed by treatment with typical and atypical antipsychotic drugs (APDs) which on their own potentiate LI. These phenomena are paralleled by disrupted LI in normal amphetamine-treated humans, in high schizotypal humans, and in schizophrenia patients in the acute stages of the disorder, as well as by potentiated LI in normal humans treated with APDs. Consequently, disrupted LI is considered to provide an animal model of positive symptoms of schizophrenia with face, construct and predictive validity.
OBJECTIVES: To review most of the rodent data on the neural substrates of LI as well as on the effects of APDs on this phenomenon with an attempt to interpret and integrate these data within the framework of the switching model of LI; to show that there are two distinct LI models, disrupted and abnormally persistent LI; to relate these findings to the clinical condition.
RESULTS: The nucleus accumbens (NAC) and its DA innervation form a crucial component of the neural circuitry of LI, and are involved at the conditioning stage. There is a clear functional differentiation between the NAC shell and core subregions whereby damage to the shell disrupts LI and damage to the core renders LI abnormally persistent under conditions that disrupt LI in normal rats. The effects of shell and core lesions parallel those produced by lesions to the major sources of input to the NAC: entorhinal cortex lesion, like shell lesion, disrupts LI, whereas hippocampal lesion, like core lesion, produces persistent LI with changes in context, and basolateral amygdala (BLA) lesion, like core lesion, produces persistent LI with extended conditioning. Systemically induced blockade of glutamatergic as well as DA transmission produce persistent LI via effects exerted at the conditioning stage, whereas enhancement of DA transmission disrupts LI via effects at the conditioning stage. Serotonergic manipulations can disrupt or potentiate LI via effects at the pre-exposure stage. Both typical and atypical APDs potentiate LI via effects at conditioning whereas atypical APDs in addition disrupt LI via effects at pre-exposure. Schizophrenia patients can exhibit disrupted or normal LI as a function of the state of the disorder (acute versus chronic), as well as persistent LI.
CONCLUSIONS: Different drug and lesion manipulations produce two poles of abnormality in LI, namely, disrupted LI under conditions which lead to LI in normal rats, and abnormally persistent LI under conditions which disrupt it in normal rats. Disrupted and persistent LI are differentially responsive to APDs, with the former reversed by both typical and atypical APDs and the latter selectively reversed by atypical APDs. It is suggested that this "two-headed LI model" mimics two extremes of deficient cognitive switching seen in schizophrenia, excessive and retarded switching between associations, mediated by dysfunction of different brain circuitries, and can serve to model positive symptoms of schizophrenia and typical antipsychotic action, as well as negative symptoms of schizophrenia and atypical antipsychotic action.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601500     DOI: 10.1007/s00213-002-1313-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  375 in total

Review 1.  The basal ganglia: a vertebrate solution to the selection problem?

Authors:  P Redgrave; T J Prescott; K Gurney
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

2.  Differential responsiveness of dopamine transmission to food-stimuli in nucleus accumbens shell/core compartments.

Authors:  V Bassareo; G Di Chiara
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

Review 3.  Perplexing effects of hippocampal lesions on latent inhibition: a neural network solution.

Authors:  C V Buhusi; J A Gray; N A Schmajuk
Journal:  Behav Neurosci       Date:  1998-04       Impact factor: 1.912

4.  Differential performance of acute and chronic schizophrenics in a latent inhibition task.

Authors:  I Baruch; D R Hemsley; J A Gray
Journal:  J Nerv Ment Dis       Date:  1988-10       Impact factor: 2.254

5.  Clozapine and haloperidol reinstate latent inhibition following its disruption during amphetamine withdrawal.

Authors:  Holger Russig; Carol A Murphy; Joram Feldon
Journal:  Neuropsychopharmacology       Date:  2002-06       Impact factor: 7.853

6.  Differential actions of dizocilpine (MK-801) on the mesolimbic and mesocortical dopamine systems: role of neuronal activity.

Authors:  J M Mathé; G G Nomikos; K H Blakeman; T H Svensson
Journal:  Neuropharmacology       Date:  1999-01       Impact factor: 5.250

7.  The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus.

Authors:  K Antoniou; S Bekris; M Saranti; P Stathis; M Rimikis; Z Papadopoulou-Daifoti
Journal:  Eur Neuropsychopharmacol       Date:  2000-09       Impact factor: 4.600

Review 8.  Latent inhibition in humans: data, theory, and implications for schizophrenia.

Authors:  R E Lubow; J C Gewirtz
Journal:  Psychol Bull       Date:  1995-01       Impact factor: 17.737

9.  Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms.

Authors:  D S Janowsky; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1976-03

10.  Effects of the selective dopamine D(1) antagonists NNC 01-0112 and SCH 39166 on latent inhibition in the rat.

Authors:  Karen M Trimble; Robert Bell; David J King
Journal:  Physiol Behav       Date:  2002-09
View more
  114 in total

Review 1.  The environment and susceptibility to schizophrenia.

Authors:  Alan S Brown
Journal:  Prog Neurobiol       Date:  2010-10-16       Impact factor: 11.685

2.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

3.  Involvement of D1 and D2 dopamine receptor in the retrieval processes in latent inhibition.

Authors:  E Diaz; J Medellín; N Sánchez; J P Vargas; J C López
Journal:  Psychopharmacology (Berl)       Date:  2015-09-08       Impact factor: 4.530

Review 4.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

5.  Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.

Authors:  Segev Barak; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

6.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

7.  Coantagonism of glutamate receptors and nicotinic acetylcholinergic receptors disrupts fear conditioning and latent inhibition of fear conditioning.

Authors:  Thomas J Gould; Michael C Lewis
Journal:  Learn Mem       Date:  2005 Jul-Aug       Impact factor: 2.460

8.  Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia.

Authors:  Tatiana Lipina; Viviane Labrie; Ina Weiner; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

9.  A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.

Authors:  Tatiana Lipina; John Roder
Journal:  Psychopharmacology (Berl)       Date:  2009-12-16       Impact factor: 4.530

10.  Learned irrelevance and associative learning is attenuated in individuals at risk for psychosis but not in asymptomatic first-degree relatives of schizophrenia patients: translational state markers of psychosis?

Authors:  Ariane T Orosz; Joram Feldon; Andor E Simon; Leonie M Hilti; Kerstin Gruber; Benjamin K Yee; Katja Cattapan-Ludewig
Journal:  Schizophr Bull       Date:  2010-01-15       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.